Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-745 dose-ranging PET amyloid study in MCI due to AD or mild Alzheimer's disease
NL-OMON44613Phase 2Active, not recruiting
- Sponsor
- CervoMed
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of neflamapimod in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (2 arms), sponsored by CervoMed. Primary endpoints: Change in quantitative relative cortical uptake of 11C-PiB and PET responder rate. Started May 2015; status: active, not recruiting.
02
Drugs
neflamapimod
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NL-OMON44613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44613.